Loading...
Glimipride 2mg + Voglibose 0.2mg + Metformin 500mg (Sr)
A triple-action oral antidiabetic formulation designed for effective management of type 2 diabetes mellitus. STELVOG 2.2 combines glimepiride, sustained-release metformin, and voglibose to enhance insulin secretion, reduce hepatic glucose production, and control post-meal blood glucose spikes.
A triple-action oral antidiabetic formulation designed for effective management of type 2 diabetes mellitus. STELVOG 2.2 combines glimepiride, sustained-release metformin, and voglibose to enhance insulin secretion, reduce hepatic glucose production, and control post-meal blood glucose spikes.
Contains Glimepiride (sulfonylurea), Metformin SR (biguanide), and Voglibose (α-glucosidase inhibitor), providing a comprehensive multi-mechanism approach for controlling blood glucose levels in type 2 diabetes.
Glimepiride stimulates pancreatic β-cells to release insulin, helping lower elevated blood glucose levels, particularly after meals.
Metformin decreases glucose production in the liver and improves insulin sensitivity in peripheral tissues, enabling better glucose utilization by body cells.
Voglibose inhibi...
Product descriptions, dosage forms, and compositions listed on the website are for reference by licensed practitioners and distributors only.
